In a memo posted to X on Monday morning, the secretary of state said 5,200 contracts had been canceled following a six-week ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Mar. 12, 2025 — A lung function test used to help diagnose asthma works better in the morning, becoming less reliable throughout the day, researchers have found. Using real world data from 1,600 ...

In patients with head and neck squamous cell carcinoma (HNSCC), low-dose CT achieved higher sensitivity than chest x-ray for detecting lung metastases and second primary lung cancer, but patients ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Feb. 18, 2025 — Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.